<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223469</url>
  </required_header>
  <id_info>
    <org_study_id>VP-001 147</org_study_id>
    <nct_id>NCT01223469</nct_id>
  </id_info>
  <brief_title>TOCCATA - Touch+™ for Catheter Ablation</brief_title>
  <acronym>TOCCATA</acronym>
  <official_title>A Prospective Safety, Performance and Preliminary Effectiveness, Multi-centre, Clinical Investigation Using the Irrigated TactiCath™ Percutaneous Ablation Catheter for the Treatment of Supra-Ventricular Tachyarrhythmia Using RF Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endosense</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to demonstrate the clinical safety of a contact force
      sensing RF ablation catheter when used for the treatment of supraventricular tachycardia and
      atrial fibrillation. In addition, the study will characterize the use and value of contact
      force measurement during ablation, and the long term success (12 months) of the ablation
      procedure using this technology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety: The primary safety endpoint assesses the incidence of procedure or device related
      SAEs from procedure to 7 (±1) days post-procedure or hospital discharge, whichever is longer,
      for patients with right-sided SVT or 3 months (±2 weeks) post-procedure for patients with
      atrial fibrillation. Secondary safety objectives were to demonstrate safety (operative and
      post-operative complications) over the 12 months post-procedure.

      Performance: The primary performance endpoint is to demonstrate successful catheter
      deployment, irrigation and ablation at the target area during supra-ventricular cardiac
      ablation. The secondary performance endpoint is to demonstrate successful and effective
      contact force reading between catheter tip and heart wall during mapping and ablation at all
      locations and all angulations.

      Efficacy: Secondary effectiveness objectives will consider acute and chronic elimination of
      the target arrhythmia, the cost-effectiveness of the system and procedure-related parameters
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Operative and Post-operative Serious Adverse Events</measure>
    <time_frame>3 months for AF arm; 7 days for the right SVT arm</time_frame>
    <description>For Right SVT patients 7 days (±1 day) following the index procedure or until hospital discharge whichever is longer.
For AF patients 3 months (±2 weeks)following the index procedure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Tachycardia, Supraventricular</condition>
  <arm_group>
    <arm_group_label>Atrial Fibrillation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Right-sided Supraventricular Tachycardia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Contact force assisted irrigated RF ablation</intervention_name>
    <description>radiofrequency ablation of atrial fibrillation or SVT</description>
    <arm_group_label>Atrial Fibrillation</arm_group_label>
    <arm_group_label>Right-sided Supraventricular Tachycardia</arm_group_label>
    <other_name>TactiCath®</other_name>
    <other_name>TactiSys®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with right-sided SVT (including: atrioventricular nodal re entry tachycardia
             [AVNRT], accessory pathway Wolff Parkinson White [WPW] syndrome, atrial tachycardia or
             isthmus-dependent atrial flutter) or paroxysmal atrial fibrillation

        Exclusion Criteria:

          -  Recent (within 3 months) cardiac events including myocardial infarction, acute
             coronary syndrome, percutaneous coronary intervention, or valve or coronary bypass
             graft surgery

          -  Moderate or severe structural heart disease (ventricular dysfunction or valve disease)
             as demonstrated by transthoracic (TTE) or transesophageal echocardiogram (TEE) of all
             four chambers of the heart

          -  Known cerebrovascular disease, including a history of stroke or transient ischemic
             attack

          -  Left ventricular ejection fraction of &lt;35%

          -  Previous heart ablation procedure (surgical or catheter) to the target chamber
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Heinz Kuck, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Klinik St. Georg, Hamburg, Germany</affiliation>
  </overall_official>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22820056</url>
    <description>Reddy VY, et. al, The relationship between contact force and clinical outcome during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA study.Heart Rhythm. 2012 Nov;9(11):1789-95</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21872560</url>
    <description>Kuck KH, et.al; A novel radiofrequency ablation catheter using contact force sensing: Toccata study. Heart Rhythm. 2012 Jan;9(1):18-23</description>
  </link>
  <results_reference>
    <citation>Reddy VY, Shah D, Kautzner J, Schmidt B, Saoudi N, Herrera C, Jaïs P, Hindricks G, Peichl P, Yulzari A, Lambert H, Neuzil P, Natale A, Kuck KH. The relationship between contact force and clinical outcome during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA study. Heart Rhythm. 2012 Nov;9(11):1789-95. doi: 10.1016/j.hrthm.2012.07.016. Epub 2012 Jul 20.</citation>
    <PMID>22820056</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuck KH, Reddy VY, Schmidt B, Natale A, Neuzil P, Saoudi N, Kautzner J, Herrera C, Hindricks G, Jaïs P, Nakagawa H, Lambert H, Shah DC. A novel radiofrequency ablation catheter using contact force sensing: Toccata study. Heart Rhythm. 2012 Jan;9(1):18-23. doi: 10.1016/j.hrthm.2011.08.021. Epub 2011 Aug 26.</citation>
    <PMID>21872560</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <results_first_submitted>March 24, 2014</results_first_submitted>
  <results_first_submitted_qc>May 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2014</results_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Supraventricular Tachycardia</keyword>
  <keyword>Contact Force</keyword>
  <keyword>RF Ablation</keyword>
  <keyword>Radiofrequency</keyword>
  <keyword>Pulmonary Vein Isolation</keyword>
  <keyword>Paroxysmal Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Supraventricular</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Atrial Fibrillation</title>
          <description>Contact force assisted irrigated RF ablation: radiofrequency ablation of atrial fibrillation.</description>
        </group>
        <group group_id="P2">
          <title>Right-sided Supraventricular Tachycardia</title>
          <description>Contact force assisted irrigated RF ablation: radiofrequency ablation of SVT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atrial Fibrillation</title>
          <description>Contact force assisted irrigated RF ablation: radiofrequency ablation of atrial fibrillation.</description>
        </group>
        <group group_id="B2">
          <title>Right-sided Supraventricular Tachycardia</title>
          <description>Contact force assisted irrigated RF ablation: radiofrequency ablation of SVT</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Operative and Post-operative Serious Adverse Events</title>
        <description>For Right SVT patients 7 days (±1 day) following the index procedure or until hospital discharge whichever is longer.
For AF patients 3 months (±2 weeks)following the index procedure.</description>
        <time_frame>3 months for AF arm; 7 days for the right SVT arm</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atrial Fibrillation</title>
            <description>Contact force assisted irrigated RF ablation: radiofrequency ablation of atrial fibrillation.</description>
          </group>
          <group group_id="O2">
            <title>Right-sided Supraventricular Tachycardia</title>
            <description>Contact force assisted irrigated RF ablation: radiofrequency ablation of SVT.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Operative and Post-operative Serious Adverse Events</title>
          <description>For Right SVT patients 7 days (±1 day) following the index procedure or until hospital discharge whichever is longer.
For AF patients 3 months (±2 weeks)following the index procedure.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atrial Fibrillation</title>
          <description>Contact force assisted irrigated RF ablation: radiofrequency ablation of atrial fibrillation.</description>
        </group>
        <group group_id="E2">
          <title>Right-sided Supraventricular Tachycardia</title>
          <description>Contact force assisted irrigated RF ablation: radiofrequency ablation of SVT.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <description>In the SVT arm, the SAE was a sinus bradycardia, followed by pacemaker implantation in a patient treated for atrial flutter with the study device and with a standard ablation catheter for concomitant RA arrhythmias.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Groin Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hendrik Lambert PhD, VP of Clinical and Regulatory Affairs</name_or_title>
      <organization>St. Jude Medical/Endosense</organization>
      <email>Hendrik.Lambert@endosense.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

